BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38267330)

  • 1. A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan.
    Haranaka M; Young Song J; Huang KC; de Solom R; Yamaji M; McElwee K; Kline M; Aizawa M; Peng Y; Scully I; Kogawara O; Gruber WC; Scott DA; Watson W
    Vaccine; 2024 Feb; 42(5):1071-1077. PubMed ID: 38267330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years.
    Essink B; Sabharwal C; Cannon K; Frenck R; Lal H; Xu X; Sundaraiyer V; Peng Y; Moyer L; Pride MW; Scully IL; Jansen KU; Gruber WC; Scott DA; Watson W
    Clin Infect Dis; 2022 Aug; 75(3):390-398. PubMed ID: 34940806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination.
    Cannon K; Elder C; Young M; Scott DA; Scully IL; Baugher G; Peng Y; Jansen KU; Gruber WC; Watson W
    Vaccine; 2021 Dec; 39(51):7494-7502. PubMed ID: 34839993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age.
    Klein NP; Peyrani P; Yacisin K; Caldwell N; Xu X; Scully IL; Scott DA; Jansen KU; Gruber WC; Watson W
    Vaccine; 2021 Sep; 39(38):5428-5435. PubMed ID: 34315611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age.
    Hurley D; Griffin C; Young M; Scott DA; Pride MW; Scully IL; Ginis J; Severs J; Jansen KU; Gruber WC; Watson W
    Clin Infect Dis; 2021 Oct; 73(7):e1489-e1497. PubMed ID: 32716500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 3 Safety and Immunogenicity Study of a Three-dose Series of Twenty-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers.
    Korbal P; Wysocki J; Jackowska T; Kline M; Tamimi N; Drozd J; Lei L; Peng Y; Giardina PC; Gruber W; Scott D; Watson W
    Pediatr Infect Dis J; 2024 Jun; 43(6):587-595. PubMed ID: 38456705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase Three Study of the Safety and Immunogenicity of a Four-dose Series of 20-Valent Pneumococcal Conjugate Vaccine in Healthy Infants.
    Senders S; Klein NP; Tamimi N; Thompson A; Baugher G; Trammel J; Peng Y; Giardina P; Scully IL; Pride M; Center KJ; Gruber WC; Scott DA; Watson W
    Pediatr Infect Dis J; 2024 Jun; 43(6):596-603. PubMed ID: 38535409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trial.
    Cannon K; Cardona JF; Yacisin K; Thompson A; Belanger TJ; Lee DY; Peng Y; Moyer L; Ginis J; Gruber WC; Scott DA; Watson W
    Vaccine; 2023 Mar; 41(13):2137-2146. PubMed ID: 36828719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).
    Platt HL; Cardona JF; Haranaka M; Schwartz HI; Narejos Perez S; Dowell A; Chang CJ; Dagan R; Tamms GM; Sterling T; Morgan L; Shi Y; Pedley A; Musey LK; Buchwald UK
    Vaccine; 2022 Jan; 40(1):162-172. PubMed ID: 34507861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.
    Jackson LA; Gurtman A; van Cleeff M; Frenck RW; Treanor J; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3594-602. PubMed ID: 23688525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 3, Single-arm Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine in Healthy Children 15 Months Through <18 Years of Age.
    Meyer J; Silas P; Ouedraogo GL; McElwee K; Keep G; Trammel J; Peng Y; Scully IL; Gruber WC; Scott DA; Watson W
    Pediatr Infect Dis J; 2024 Jun; 43(6):574-581. PubMed ID: 38502894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States.
    Fitz-Patrick D; Young M; Scott DA; Scully IL; Baugher G; Peng Y; Jansen KU; Gruber W; Watson W
    Hum Vaccin Immunother; 2021 Jul; 17(7):2249-2256. PubMed ID: 33545022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 3 randomized study to evaluate safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in healthy Japanese infants.
    Ishihara Y; Fukazawa M; Enomoto S; de Solom R; Yamaji M; Kline M; Aizawa M; Peng Y; Kogawara O; Giardina PC; Tamimi N; Gruber WC; Watson W
    Int J Infect Dis; 2024 Apr; 141():106942. PubMed ID: 38242195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.
    Platt H; Omole T; Cardona J; Fraser NJ; Mularski RA; Andrews C; Daboul N; Gallagher N; Sapre A; Li J; Polis A; Fernsler D; Tamms G; Xu W; Murphy R; Skinner J; Joyce J; Musey L
    Lancet Infect Dis; 2023 Feb; 23(2):233-246. PubMed ID: 36116461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults.
    Thompson A; Lamberth E; Severs J; Scully I; Tarabar S; Ginis J; Jansen KU; Gruber WC; Scott DA; Watson W
    Vaccine; 2019 Sep; 37(42):6201-6207. PubMed ID: 31495592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial.
    Thompson AR; Klein NP; Downey HJ; Patterson S; Sundaraiyer V; Watson W; Clarke K; Jansen KU; Sebastian S; Gruber WC; Scott DA; Schmöele-Thoma B
    Hum Vaccin Immunother; 2019; 15(2):444-451. PubMed ID: 30303436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH).
    Song JY; Chang CJ; Andrews C; Diez-Domingo J; Oh MD; Dagan R; Hartzel J; Pedley A; Li J; Sterling T; Tamms G; Chiarappa JA; Lutkiewicz J; Musey L; Tu Y; Buchwald UK;
    Vaccine; 2021 Oct; 39(43):6422-6436. PubMed ID: 34489128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial.
    Wassil J; Sisti M; Fairman J; Davis M; Fierro C; Bennett S; Johnson D; Migone TS; Nguyen K; Sauer P; Currie M; Iki S; Simon JK
    Lancet Infect Dis; 2024 Mar; 24(3):308-318. PubMed ID: 38061367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.